5-AR inhibitor reduces risk of BPH-associated events

Chicago-Real-world clinical practice data provide further evidencethat treatment with a 5-alpha-reductase inhibitor significantly reducesthe risks for progression to acute urinary retention (AUR), catheterization,or surgery in men with BPH, according to a retrospective analysis from theUnited Kingdom.

Related Content:

Drug Therapy

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa